Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
5.36
Dollar change
+0.52
Percentage change
10.74
%
Index- P/E- EPS (ttm)-14.31 Insider Own8.80% Shs Outstand2.97M Perf Week26.71%
Market Cap15.92M Forward P/E- EPS next Y-2.70 Insider Trans3.89% Shs Float2.71M Perf Month15.64%
Income2.28M PEG- EPS next Q-0.81 Inst Own48.42% Short Float0.62% Perf Quarter-6.81%
Sales16.00M P/S0.99 EPS this Y103.97% Inst Trans0.65% Short Ratio0.63 Perf Half Y3.57%
Book/sh11.96 P/B0.45 EPS next Y-381.25% ROA9.52% Short Interest0.02M Perf Year-21.47%
Cash/sh10.53 P/C0.51 EPS next 5Y- ROE12.46% 52W Range3.60 - 8.98 Perf YTD14.00%
Dividend Est.- P/FCF2.23 EPS past 5Y56.98% ROI6.51% 52W High-40.33% Beta-0.21
Dividend TTM- Quick Ratio21.02 Sales past 5Y-27.40% Gross Margin99.23% 52W Low48.89% ATR (14)0.55
Dividend Ex-Date- Current Ratio21.02 EPS Y/Y TTM90.77% Oper. Margin38.92% RSI (14)62.88 Volatility20.34% 12.32%
Employees12 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin14.23% Recom1.00 Target Price33.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q138.31% Payout- Rel Volume4.65 Prev Close4.84
Sales Surprise0.00% EPS Surprise38.18% Sales Q/Q- EarningsMay 10 BMO Avg Volume26.46K Price5.36
SMA2015.01% SMA5013.65% SMA2004.19% Trades Volume122,929 Change10.74%
May-29-24 06:44PM
May-20-24 07:00AM
May-10-24 01:54PM
07:00AM
May-08-24 07:00AM
07:00AM Loading…
May-06-24 07:00AM
Apr-11-24 07:00AM
Apr-05-24 07:00AM
Mar-28-24 06:45AM
Mar-25-24 07:00AM
Mar-08-24 07:00AM
Feb-01-24 08:14AM
Jan-31-24 06:40PM
05:15PM
Nov-17-23 01:54PM
07:18AM Loading…
Nov-09-23 07:18AM
Nov-04-23 12:15PM
Oct-16-23 07:00AM
Oct-03-23 07:00AM
Sep-21-23 07:00AM
Sep-18-23 07:00AM
Sep-14-23 07:01AM
Sep-01-23 07:00AM
Aug-29-23 01:43PM
Aug-23-23 07:33PM
07:00AM
Aug-22-23 01:06PM
Aug-16-23 07:00AM
Aug-08-23 07:00AM
Aug-03-23 07:00AM
07:00AM Loading…
Aug-01-23 07:00AM
Jul-05-23 07:00AM
Jun-23-23 08:35AM
Jun-20-23 10:58AM
Jun-15-23 07:00AM
Jun-14-23 08:00AM
Jun-06-23 04:30PM
Jun-02-23 08:30AM
May-09-23 07:00AM
May-01-23 07:00AM
Apr-27-23 02:55PM
Apr-26-23 07:00AM
Apr-21-23 07:00AM
Apr-17-23 07:00AM
Mar-30-23 07:00AM
Mar-23-23 07:00AM
Mar-10-23 07:00AM
Feb-09-23 12:00PM
Feb-07-23 08:00AM
07:00AM
Feb-03-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:01AM
Dec-14-22 08:19AM
Nov-18-22 08:30AM
Nov-17-22 06:45AM
Nov-09-22 06:45AM
Oct-31-22 08:01AM
Oct-17-22 08:00AM
Oct-13-22 06:45AM
Sep-28-22 11:44AM
Sep-26-22 06:45AM
Sep-13-22 06:45AM
Aug-15-22 06:30AM
Aug-12-22 06:45AM
Jul-28-22 06:45AM
Jul-26-22 04:38PM
Jul-22-22 08:30AM
Jul-05-22 06:45AM
Jun-27-22 06:53AM
May-31-22 04:30PM
Apr-25-22 06:45AM
Apr-15-22 09:00AM
Mar-21-22 06:45AM
Mar-18-22 12:00PM
06:45AM
Feb-08-22 06:45AM
Feb-01-22 06:45AM
Jan-05-22 07:00AM
Dec-15-21 07:00AM
Dec-14-21 07:15AM
Nov-15-21 07:30AM
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Daniels Eric JosephChief Development OfficerJun 14 '24Buy5.291,4317,57011,222Jun 14 03:40 PM
Tosca MelissaEVP FinanceJun 14 '24Buy5.251005253,979Jun 14 04:47 PM
Parsons ErinDirectorJun 13 '24Buy4.885,26025,6695,260Jun 13 03:51 PM
Strem Brian M.President and CEOJun 13 '24Buy5.003,00014,99714,531Jun 13 03:49 PM